Answers are grounded in this paper and cite their sources.
The AHA's new CKM syndrome staging system aims to break down subspecialty silos and promote holistic, unified management of interconnected cardiovascular, kidney, and metabolic conditions.
Although clinicians and researchers have recognized the intersection between cardiovascular, kidney, and metabolic (CKM) conditions, cardiology, nephrology, and endocrinology professionals generally work in siloed healthcare environments separated from primary care, which often leads to fragmented care. In response to this issue, the American Heart Association (AHA) released a presidential advisory and scientific statement in 2023 to define CKM syndrome and introduce a CKM staging system.1-3 CKM syndrome is defined as “a health disorder due to connections among heart disease, kidney disease, diabetes and obesity leading to poor health outcomes.”1 The CKM staging system succinctly shows the interplay between metabolic diseases (obesity and diabetes), chronic kidney disease (CKD), and cardiovascular disease (CVD), defined as atherosclerotic CVD plus heart failure (see Figure 1). Collectively, these conditions contribute to increased morbidity, premature mortality, and increased healthcare costs.4 To improve the outcome trajectory of patients with CKM syndrome, AHA’s presidential advisory and scientific statement unifies terminology and definitions, bridges gaps, and harmonizes across specialty-focused guidelines while also promoting the holistic management of patients at any stage of CKM syndrome (stages 0-4) (see Figures 2 and 3). Emphasis is placed on reducing subspecialty silos and increasing recognition of and screening for CKM risk factors.1 Key aspects of this statement are provided in Box 1.1
No takes yet. Share an insight, caveat, or question.
Maxson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: